Biotech · Private company
Advaxis, Inc.
Track this companyFree. Adds Advaxis, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials90 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- ADXS11-001Phase 3 · High Risk Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- ADXS-503Phase 2 · Lung Cancer, Non-Small CellClinicalTrials.gov · fetched Nov 12, 2026
- ADXS11-001Phase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- ADXS31-142Phase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- ADXS31-164Phase 2 · HER2 Expressing Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Axalimogene filolisbacPhase 2 · Anal CancerClinicalTrials.gov · fetched Nov 12, 2026
- MEDI4736Phase 2 · Cervical CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Lung Cancer, Non-Small CellClinicalTrials.gov · fetched Nov 12, 2026
- ADXS-NEOPhase 1 · Colon Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- Axalimogene filolisbacPhase 1 · Effects of ImmunotherapyClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Colon Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung CancerPHASE1_PHASE2 · COMPLETED · started Feb 12, 2019ClinicalTrials.gov NCT03847519 · fetched Nov 12, 2026
- A Study of ADXS-NEO Expressing Personalized Tumor AntigensPHASE1 · TERMINATED · started Mar 28, 2018ClinicalTrials.gov NCT03265080 · fetched Nov 12, 2026
- A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal CanalPHASE2 · COMPLETED · started Jun 2, 2016ClinicalTrials.gov NCT02399813 · fetched Nov 12, 2026
- Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical CancerPHASE3 · TERMINATED · started Dec 15, 2015ClinicalTrials.gov NCT02853604 · fetched Nov 12, 2026
- Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid TumorsPHASE1_PHASE2 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02386501 · fetched Nov 12, 2026
- ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)PHASE1_PHASE2 · COMPLETED · started Jun 4, 2015ClinicalTrials.gov NCT02325557 · fetched Nov 12, 2026
- A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck CancerPHASE1_PHASE2 · TERMINATED · started Apr 1, 2015ClinicalTrials.gov NCT02291055 · fetched Nov 12, 2026
- Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerPHASE1 · COMPLETED · started Mar 4, 2015ClinicalTrials.gov NCT02164461 · fetched Nov 12, 2026
- ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal CancerPHASE2 · COMPLETED · started Dec 1, 2013ClinicalTrials.gov NCT02002182 · fetched Nov 12, 2026